OBJECTIVE: Based on the frequency of immune-mediated and non-immune-mediated transfusion-related acute lung injury (TRALI), the effect of risk-minimization measures was evaluated during a period of 5 years (2006-2010). Risk-minimization measures were implemented in 2008/2009, consisting of exclusion of female donors with a history of pregnancy or exclusion of female donors with human leucocyte antigen (HLA)/human neutrophil alloantigen (HNA) antibodies. METHODS: TRALI was confirmed according to the criteria of the International Haemovigilance Network. Based upon the results of donor testing of white-blood-cell antibodies (WBC-Ab) against HLA or HNAs, confirmed cases were classified as immune- or non-immune-mediated TRALI. Reporting rates were calculated on the basis of the annually transfused blood components, and pre- and post-implementation periods were compared. RESULTS: In total, 60 immune-mediated (75%) and 20 non-immune-mediated (25%) TRALI reactions were confirmed. A total of 68 (64 women and four men) donors were involved: seven red-blood-cell concentrates donors (13%), six platelet concentrate donors (10%), and 48 fresh frozen plasma (FFP) donors (77%). The reporting rate of immune-mediated TRALI caused by FFP decreased continuously; from 12·71 per million units in 2006/2007 to 6·81 per million units in 2008/2009 and no case in 2010. CONCLUSION: The comparison of the pre- and the post-implementation period demonstrated a significantly reduced risk of TRALI events comparing 2006/2007 with 2010 (P-value: <0·01). Furthermore, no case of TRALI-induced fatality occurred after the implementation of risk-minimization measures.
OBJECTIVE: Based on the frequency of immune-mediated and non-immune-mediated transfusion-related acute lung injury (TRALI), the effect of risk-minimization measures was evaluated during a period of 5 years (2006-2010). Risk-minimization measures were implemented in 2008/2009, consisting of exclusion of female donors with a history of pregnancy or exclusion of female donors with human leucocyte antigen (HLA)/human neutrophil alloantigen (HNA) antibodies. METHODS: TRALI was confirmed according to the criteria of the International Haemovigilance Network. Based upon the results of donor testing of white-blood-cell antibodies (WBC-Ab) against HLA or HNAs, confirmed cases were classified as immune- or non-immune-mediated TRALI. Reporting rates were calculated on the basis of the annually transfused blood components, and pre- and post-implementation periods were compared. RESULTS: In total, 60 immune-mediated (75%) and 20 non-immune-mediated (25%) TRALI reactions were confirmed. A total of 68 (64 women and four men) donors were involved: seven red-blood-cell concentrates donors (13%), six platelet concentrate donors (10%), and 48 fresh frozen plasma (FFP) donors (77%). The reporting rate of immune-mediated TRALI caused by FFP decreased continuously; from 12·71 per million units in 2006/2007 to 6·81 per million units in 2008/2009 and no case in 2010. CONCLUSION: The comparison of the pre- and the post-implementation period demonstrated a significantly reduced risk of TRALI events comparing 2006/2007 with 2010 (P-value: <0·01). Furthermore, no case of TRALI-induced fatality occurred after the implementation of risk-minimization measures.
Authors: Chris Edens; Kathryn A Haass; Melissa Cumming; Anthony Osinski; Lynne O'Hearn; Kelly Passanisi; Lynn Eaton; Paul Visintainer; Alexandra Savinkina; Matthew J Kuehnert; Sridhar V Basavaraju; Chester Andrzejewski Journal: Transfusion Date: 2018-11-14 Impact factor: 3.157
Authors: Pearl Toy; Mark R Looney; Mark Popovsky; Miodrag Palfi; Gösta Berlin; Catherine E Chapman; Paula Bolton-Maggs; Michael A Matthay Journal: Ann Am Thorac Soc Date: 2022-05
Authors: Alexander P J Vlaar; Pearl Toy; Mark Fung; Mark R Looney; Nicole P Juffermans; Juergen Bux; Paula Bolton-Maggs; Anna L Peters; Christopher C Silliman; Daryl J Kor; Steve Kleinman Journal: Transfusion Date: 2019-04-16 Impact factor: 3.157
Authors: Maximilian Dietrich; Tobias Hölle; Lazar Detelinov Lalev; Martin Loos; Felix Carl Fabian Schmitt; Mascha Onida Fiedler; Thilo Hackert; Daniel Christoph Richter; Markus Alexander Weigand; Dania Fischer Journal: J Clin Med Date: 2022-07-27 Impact factor: 4.964
Authors: Lilian Jo Engelhardt; Claudio Olbricht; Marcel Niemann; Jan Adriaan Graw; Oliver Hunsicker; Björn Weiss; Victoria Bünger; Steffen Weber-Carstens; Sebastian Daniel Boie; Sophie K Piper; Felix Balzer; Mario Menk Journal: J Clin Med Date: 2022-09-28 Impact factor: 4.964